Montreal, Canada-based AmorChem II Ventures, Inc., has launched a life sciences venture capital fund specialized in seed-stage biotechnology investing.
AmorChem II Fund L.P., has an initial capitalization of $44.2m and is backed by the Québec government, Fonds de solidarité FTQ, Merck and other qualified investors.
Led by founding partners Elizabeth Douville and Inès Holzbaur, AmorChem II will focus on investing in promising life sciences projects originating from Québec-based universities and research centres.
Its innovative business model involves financing and actively managing these projects in order to build attractive biotechnology start-ups able to attract financial investors and pharmaceutical partners.
With the launch of AmorChem II, Maxime Ranger, PhD, MBA, a seasoned biotechnology entrepreneur, joined as a General Partner.